Publications
Detailed Information
Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tahara, Makoto | - |
dc.contributor.author | Muro, Kei | - |
dc.contributor.author | Hasegawa, Yasuhisa | - |
dc.contributor.author | Chung, Hyun Cheol | - |
dc.contributor.author | Lin, Chia-Chi | - |
dc.contributor.author | Keam, Bhumsuk | - |
dc.contributor.author | Takahashi, Kenichi | - |
dc.contributor.author | Cheng, Jonathan D. | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.date.accessioned | 2021-01-31T11:06:53Z | - |
dc.date.available | 2021-01-31T11:06:53Z | - |
dc.date.created | 2019-07-01 | - |
dc.date.issued | 2018-03 | - |
dc.identifier.citation | Cancer Science, Vol.109 No.3, pp.771-776 | - |
dc.identifier.issn | 1347-9032 | - |
dc.identifier.other | 77152 | - |
dc.identifier.uri | https://hdl.handle.net/10371/173032 | - |
dc.description.abstract | KEYNOTE-012 was a phase Ib, multicohort study designed to investigate efficacy and safety of pembrolizumab in advanced solid tumors. Results from the subset of patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) from the Asia-Pacific region are reported. Patients with recurrent/metastatic HNSCC, measurable disease (RECIST version 1.1), and ECOG performance status (PS) 0-1 were eligible for enrollment in the HNSCC expansion cohort. Patients received pembrolizumab 200 mg every 3 weeks. Response was assessed every 8 weeks. Co-primary end-points were safety and overall response rate (RECIST version 1.1, central review). Secondary end-points included overall survival and response duration. Patients enrolled at any of the five centers throughout the Asia-Pacific region were included in these analyses. Twenty-six patients with HNSCC from the Asia-Pacific region received pembrolizumab. The median age was 62 years, 65% of patients had ECOG PS 1, and 62% had received two or more prior therapies for recurrent/metastatic disease. Sixteen (62%) patients experienced a treatment-related adverse event of any grade, including two (8%) patients who experienced one or more events of grade 3 severity. No treatment-related deaths occurred. The overall response rate was 19% (95% confidence interval, 7%-39%). After a median follow-up of 12 months (range, 2-21 months), a median response duration was not reached (range, 6 to 17+ months); four of five responses lasted 6 months. Median overall survival was 11.6 months (95% confidence interval, 4.7-17.7 months). Pembrolizumab was well tolerated and had durable antitumor activity in patients with HNSCC from the Asia-Pacific region. (Trial registration no. NCT01848834.) | - |
dc.language | 영어 | - |
dc.publisher | Oxford University Press | - |
dc.title | Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012 | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.identifier.doi | 10.1111/cas.13480 | - |
dc.citation.journaltitle | Cancer Science | - |
dc.identifier.wosid | 000426596800029 | - |
dc.identifier.scopusid | 2-s2.0-85041698363 | - |
dc.citation.endpage | 776 | - |
dc.citation.number | 3 | - |
dc.citation.startpage | 771 | - |
dc.citation.volume | 109 | - |
dc.identifier.sci | 000426596800029 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | CHEMOTHERAPY PLUS CETUXIMAB | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | SINGLE-ARM | - |
dc.subject.keywordPlus | PHASE 1B | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | RECURRENT | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordAuthor | Asia-Pacific | - |
dc.subject.keywordAuthor | head and neck squamous cell carcinoma | - |
dc.subject.keywordAuthor | PD-1 | - |
dc.subject.keywordAuthor | PD-L1 | - |
dc.subject.keywordAuthor | Pembrolizumab | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.